medigraphic.com
ISSN 0188-9796 (Print)

2006, Number 3

<< Back Next >>

Rev Endocrinol Nutr 2006; 14 (3)

Cancer of mamma and endometrium in menopause

Martínez SC, Dorantes CA, García SJN

Language: Spanish
References: 64
Page: 159-170
PDF size: 112.24 Kb.


Text Extraction

No abstract


REFERENCES

  1. Salud: México 2003 (evaluacion.salud.gob.mx/saludmex2003/capitulo1.pdf)

  2. Gerson R, Serrano A, Flores F, Villalobos A, Sánchez-Forgach E. Edad y cáncer mamario. Rev Med Hosp Gen Mex 1998; 61 (1): 7-13.

  3. Lobo R. Menopause and Hormone Replacement Therapy: Areas for future inquiry. Endocrinol Metab Clin N Am 2004; 33(4): 761-9.

  4. Biglia N, Defabiani E, Ponzone R, Mariani L, Marenco D, Sismondi P. Management of risk of breast carcinoma in postmenopausal women. Endocrine-Related Cancer 2004; 11: 69-83.

  5. Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. Maturitas 2001; 38: 103-16.

  6. Thompson WD. Genetic epidemiology of breast cancer. Cancer 1994; 74 (suppl 1): 279-87.

  7. Boyd N, Byng J, Jong RA, Fishell E, Little L, Miller A, Lockwood G, Tritchler D, Yaffe M. Quantitative classification of mammographic densities and breast cancer risk : results from Canadian National Breast Cancer Screening Study. Journal of the National Institute 1995; 87: 670-75.

  8. Greendale GA, Rebboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskas C, Bush T, Barrett-Connor E. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999; 130: 262-9.

  9. Wärnberg F, Bundred NJ. Oestrogen and breast cancer. JR Coll Physicians Edinb 2004; 34 (suppl 13): 25-31.

  10. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin´s disease. Cancer Treatment Reviews 2000; 26: 291-302.

  11. Diamanti-Kandarakis E, Sykiotis G, Papavassiliou A. Selective modulation of postmenopausal women (Cutting the Giordian knot of hormone replacement therapy with breast carcinoma). Cancer 2003; 97(1): 12-20.

  12. Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE. Weigth gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiology, Biomarkers & Prevention 2004; 13: 220-4.

  13. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, Hennekeus CH, Rosner B, Speizer FE, Willett WC. Dual effects of weigth and weigth gain on breast cancer risk. J Am Med Assoc 1997; 278: 321-33.

  14. Friedenreich CM, Courneya KS, Bryant HE. Case-control study of anthropometric measures and breast cancer risk. Int J Cancer 2002; 99: 445-52.

  15. Smith-Warner S, Spiegelman D, Yaun SS, Van Der Brandt PA, Folsom AR, Goldbohm RA, Graham S, Holmberg L, Howe GR, Marshall JR. Alcohol and breast cancer in women: a pooled analysis of cohort studies. J Am Med Assoc 1998; 279: 535-40.

  16. Marcus PM, Newman B, Millikan RC, Moorman PG, Baird DD, Qaqish B. The associations of adolescent cigarette smoking, alcoholic beverage consumption, environmental tobacco smoke, and ionizing radiation with subsequent breast cancer risk. Cancer Causes and Control 2000; 11: 271-8.

  17. Baron JA, Newcomb PA, Longnecker MP, Mittendorf R, Storer BE, Clapp RW, Bogdan G, Yuen J. Cigarette smoking and breast cancer. Cancer Epidemiology Biomarkers and Prevention 1996; 5: 399-403.

  18. Dirx MJ, Voorrips LE, Goldbohm RA, Van Der Brandt PA. Baseline recreational physical activity, history of sports participation and postmenopausal breast carcinoma risk in the Netherlands Cohort Study. Cancer 2001; 92: 1638-49.

  19. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reabalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997; 350: 1047-59.

  20. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormonal contraceptives: collaborative study of individual data on 53297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-27.

  21. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormonal contraceptives: further results. Contraception 1996; 54 (suppl. 3): 91-106.

  22. Van Hoften C, Burger H, Peeters PH, Grobbe DE, Van Noord PA, Leufkens HG. Long-term oral contraceptives use increases breast cancer risk in women over 55 years of age: the DOM cohort. Int J Cancer 2000; 87: 591-4.

  23. Aiello EJ, Buist DS, White E, Seger D, Taplin SH. Rate of Breast Cancer Diagnoses Among Postmenopausal Women With Self-Reported Breast. J Am Board Fam Pract 2005; 17(6): 408-15.

  24. Tice JA, Miike R, Adduci K, Petrakis NL, King E, Wrensch MR. Nipple aspirate fluid cytology and the Gail model for breast cancer risk assessment in a screening population. Cancer Epidemiology, Biomarkers & Prevention 2005; 14(2): 324-9.

  25. Tobias JS. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention. Annals of Oncology 2004; 15: 1738-47.

  26. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, et al. The effect of raloxifeno on the risk of breast cancer on postmenopausal women: results from the MORE randomized trial. J Am Med Assoc 1999: 2189-97.

  27. Gasco M, Argusti A, Bonanni B, Decensi A. SERMS in chemoprevention of breast cancer. Eur J Cancer 2005; 41(13): 1980-9.

  28. Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. The Oncologist 2004; 9: 126-36.

  29. Kudachadkar R, O´Regan R. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J Clin 2005; 55: 145-63.

  30. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Low-dose aspirin in the primary prevention of cancer: the Women´s Health Study: a randomized controlled trial. JAMA 2005; 294(1): 47-55.

  31. Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, Ibuoprofen and other non-steroidal anti-inflamatory drugs in cancer prevention : a critical review on non-selective COX-2 blockade. Oncology Reports 2004; 13: 559-83.

  32. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006; 6(1): 27. http://www.biomedcentral.com/1471-2407/6/27

  33. Lundstrom E, Wilczek B, Von Palffy Z, Sodergvist G, Von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999; 181: 348-52.

  34. Reed S, Newton C, LaCroix A. Indications for Hormone Therapy: The Post-Women´s Health Initiative Era. En: Menopause and hormone replacement therapy. Endocrinology and Metabolism Clinics of North America 2004; 33(4): 691-716.

  35. Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. Journal of Clinical Endocrinology and Metabolism 2001; 86(1): 16-23.

  36. Hofseth LJ, RaafatAhmed M, Osuch JR. Hormone Replacement therapy with Estrogen or Estrogen plus Medroxyprogesterone Acetate is associated with Increased Epithelial Proliferation in the Normal Postmenopausal Breast. Journal Clinical Endocrinology and Metabolism 1999; 84(12): 4559-4565.

  37. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskas C, Bush T, Barrett-Connor E. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Annals of Internal Medicine 1999; 130: 262-269.

  38. Chelebwski RT, Hendrix SL, Langer RD. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The women´s health initiative randomized trial. Journal American Medical Association 2003; 289(24): 3243-3253.

  39. Group for the Women´s Health Iniciative Investigators. Risk and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. Principal Results From the Women´s Health Initiative Randomized Controlled Trial. Journal American Medical Association 2002; 288(3): 321-331.

  40. Scharier C, Lubin J, Troisi R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283(4): 485-491.

  41. Coldtiz G, Hankinson SE, Hunter DJ. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New England Journal Medicine 1995; 332(24): 1589-1593.

  42. Weiss LK, Burkman RT, Cushing-Haugen KL. Hormone replacement therapy regimens and breast cancer risk. The American College of Obstetricians and Gynecologists 2002; 100(6): 1148-1158.

  43. Chi-Ling C, Noel SW, Polly N. Hormone replacement therapy in relation to breast cancer. Journal American Medical Association 2002; 287(6): 734-741.

  44. Gertig D. MBBS. Hormone replacement therapy increases breast cancer incidence and may increase breast cancer mortality in postmenopausal women. Evidence-Based healthcare 2004; 8(1): 41-42.

  45. Newcomer LM, Newcomb PA, Potter JD, et al. Postmenopausal hormone therapy an risk of breast cancer by histologic type. Cancer Causes & Control 2003; 14(3): 225-233.

  46. Shah NR, Borenstein J, Duboois RW. Postmenopausal hormone therapy and breast cancer: a systematic review and meta-analysis. Menopause 2005; 12(6): 668-678.

  47. The Women´s Health Initiative Steerin Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The women´s health initiative randomized controlled trial. Journal American Medical Association 2004; 291(14): 1701-1712.

  48. Modelska K, Cummings S. Tibolone for postmenopausal women: Systematic review of randomized trials. Journal of Clinical Endocrinology and Metabolism 2002; 87(1): 16-23.

  49. Valdivia I, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or coventional hormone replacement therapy. Clinical Durg Investigation 2000 ; 20(2): 101-107.

  50. Christodoulakos G, Lambrinoudaki I, Vourtsi A, et al. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women : a prospective study. Menopause 2002; 9(2): 110-116.

  51. Beral VBE, Reeves GB. Breast cancer and hormone-replacement therapy: the Million Women Study. Lancet 2003; 362: 419-427.

  52. Woraluk S, Davis SR. Testosterone effects on the breast: Implications of testosterone therapy for women. Endocrine Reviews 2004; 25(3): 374-388.

  53. The role of testosterone therapy in postmenopausal women: position statement of the North American Menopause Society. Menopause 2005; 12(5): 497-511.

  54. Torres LA, Hernández FF, Hernández NM, Román BE, Rojo HG, Oliva PJ, Morales PM. Cáncer del endometrio. Estado actual de frecuencia por estadios y resultados del tratamiento en el Hospital General de México. Gac Mex de Oncología 2004; 3: 92-6.

  55. Lobo R. Menopause and Hormone Replacement Therapy: Areas for future inquiry. Endocrinol Metab Clin N Am 2004; 33(4): 761-9.

  56. Albers JR, Hull SK, Wesley RM. Abnormal uterine bleeding. Am Fam Physicians 2004; 69 (8): 1915-26.

  57. Robertson G. Screening for endometrial cancer. Med J Aust 2003; 178: 657-59.

  58. Kudachadkar R, O´Regan R. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J Clin 2005; 55: 145-63.

  59. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365: 1543-51.

  60. Genazzani AR, Gadducci A, Gambacciani M and International Menopause Society Expert Workshop. Controversial Issues in Climateric Medicine II Hormone Replacement Therapy and Cancer. Climateric 2001; 4: 181-193.

  61. Sismondi P, Biglia N. HRT and Gynaecologic Cancer after WHI: Old Stuff or New Doubts? Maturitas 2004: 13-18.

  62. Ericson K, Nilbert M, Bladstrom A, Anderson H, Olsson H, Planck M. Familial risk of tumors associated with hereditary non-polyposis colorectal cancer: a Swedish population-based study. Scand J Gastroenterol 2004; 39(12): 1259-65.

  63. Gerber B, Krause A, Muller H. Ultrasonographic detection of asymptomatic endometrial cancer in postmenopausal patients offers no prognostic advantage over symptomatic disease discovered by uterine bleeding. Eur J Cancer 2001; 37: 64-71

  64. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, Lu KH. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 2005; 105(3): 575-80.




2020     |     www.medigraphic.com